MedTrace Logo

Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection

NCT02176135 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2015-02-26

No results posted yet for this study

Summary

The main purpose of the study is to evaluate the safety of oral auranofin, a gold compound, in patients with HIV infection whose viral load has been suppressed by antiretroviral therapy for no less than 3 years and have a CD4+ cell count over 500 cells/uL

Conditions

Interventions

DRUG

Auranofin

3 mg tablets

Sponsors & Collaborators

  • University of Miami

    collaborator OTHER

  • Vaccine and Gene Therapy Institute, Florida

    lead OTHER

Principal Investigators

  • Patrick D Yeramian, MD · Vaccine and Gene Therapy Institute, Florida

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Primary Completion
2016-01-31
Completion
2017-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176135 on ClinicalTrials.gov